Palisade Bio (PALI) EBT Margin (2011 - 2026)

Palisade Bio (PALI) posted quarterly EBT Margin of 15269.2% for Q1 2023, up 88.89% quarter-over-quarter from 137416.12% in Q4 2020.

Palisade Bio (PALI) EBT Margin (2011 - 2026) Analysis & Trends

Palisade Bio (PALI) has reported EBT Margin for 11 consecutive years, with 15269.2% the latest figure, recorded in Q1 2023.

In Q1 2023, EBT Margin changed N/A year-over-year to 15269.2%; the TTM figure through Dec 2023 stood at 19498.0% (changed N/A YoY), while the FY2023 annual figure was 16808.8%, changed N/A from the prior year.
EBT Margin improved to 15269.2% in Q1 2023 per PALI's latest filing, from 137416.12% in the prior quarter.
Across five years, EBT Margin topped out at 15269.2% in Q1 2023 and bottomed at 137416.12% in Q4 2020.
Historically, EBT Margin has averaged 70880.01% across 3 years, with a median of 75960.88% in 2020.
On a YoY basis, EBT Margin climbed as much as 5895662 bps in 2020 and fell as far as 5243968 bps in 2020.
Palisade Bio's EBT Margin stood at 84976.44% in 2019, then sank by 62 bps to 137416.12% in 2020, then soared by 89 bps to 15269.2% in 2023.
Business Quant data shows PALI's EBT Margin at 15269.2% in Q1 2023, 137416.12% in Q4 2020, and 73918.76% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Palisade Bio	372.94 Mn	247.74 Mn	-	-2,339.60%

Download Data